Development of an Ultra-Sensitive Simoa Assay to Enable Gdf11 Detection: A Comparison Across Bioanalytical Platforms

Abstract

This improvement was essential to enable detection of GDF11 in biological samples, and without the technology the sensitivity achieved on the other platforms would not have been sufficient. Other factors such as ease of use, cost, assay time and automation capability can also be considered when developing custom immunoassays, based on the requirements of the bioanalyst.

Microfluidic systems for the analysis of blood‐derived molecular biomarkers

“…Nano/microbeads have also been used in highly sensitive and multiplexed commercial applications, such as Dynabeads [211,249,255] and digital ELISAs (dELISA), also known as single molecule array (SiMoA) [260,261]. dELISA can trap and detect single proteins in femtolitersized wells [262,263].…”

A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence?

“…While a handful of studies have demonstrated superiority of Simoa compared to standard ELISA in these respects, very few have compared MSD HPE to Quanterix Simoa. In one study, Myzithras and colleagues found Simoa achieved higher sensitivity detecting a growth factor (GDF11), a 100-fold improvement in the lower limit of quantification compared to MSD, in standardized pooled samples 11 . Another study demonstrated that use of CSF AB42/Ab40 ratios as quantified on HPE or Simoa were comparably sensitive in classifying abnormal amyloid PET 12 .…”